ERBB2 and breast cancer: Dynamic circulating miR-21-5p levels were also investigated by Liu B. et al. in 118 patients affected by early HER2-negative BC [30] receiving four to six cycles of NAC with an association of docetaxel, epirubicin, and cyclophosphamide (TEC regimen).